Journal Home
Search for

Volume 33, Issue 1, Pages 81-86 (February 2007)


View previous. 15 of 30 View next.

Effects of gabapentin on morphine consumption and pain in severely burned patients

Olivier Cuigneta, Jean PirsonaCorresponding Author Informationemail address, Olivier Soudonb, Martin Zizic

Accepted 18 April 2006.

Abstract 

Objective

Nociception is the major cause of burn pain and leads to central hyperalgesia. Gabapentin (Gp) is an antihyperalgesic drug that selectively affects central sensitization. We studied the opioid-sparing and analgesic effects of Gp in severely burned patients.

Methods

Ten patients (mean total burned body surface area (TBSA), 25%), received 2400mg of oral Gp daily from after burn days 3–24 in addition to standard pain therapy. They were compared to a retrospective matching group. Outcomes were cumulative morphine consumption and mean daily pain scores. Outcomes were recorded during treatment (21 days) and 21 days after treatment.

Results

During treatment and post-treatment phases, patients receiving Gp had cumulative morphine consumption and a mean daily pain score significantly lower than controls.

Conclusion

Gp use reduced opioid consumption and lowered pain scores that seemed to extend beyond its pharmacologic action probably result from the ability of Gp to prevent central hyperalgesia induced by burns.

a Burn Center, Military Hospital, Rue Bruyn 1, 1120 Brussels, Belgium

b Department of Anesthesiology, Université Catholique de Louvain, Belgium

c ACOS WB, Division of Biostatistics and Epidemiology, Belgian Ministry of Defense, Belgium

Corresponding Author InformationCorresponding author. Tel.: +32 2 2644810.

PII: S0305-4179(06)00152-5

doi:10.1016/j.burns.2006.04.020


View previous. 15 of 30 View next.